Key clinical point: Compared with healthy controls, patients with chronic myeloid leukemia (CML) showed significantly higher expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) that correlated with CML disease progression.
Major finding: HNRNPH1 mRNA expression was significantly higher in patients with CML vs healthy controls ( P less than .001). HNRNPH1 expression was significantly increased in the accelerated ( P less than .05) and blast ( P less than .001) phase vs chronic phase of CML.
Study details: Findings are from an analysis of 60 patients with newly diagnosed, untreated CML and 30 healthy donors. Bone marrow mononuclear cells were extracted from patients, and mRNA expression was assessed using quantitative real-time polymerase chain reaction.
Disclosures: This study was partly supported by the Natural Science Foundation of Hebei Province. The authors declared no conflicts of interest.
Source: Liu M et al. Front Oncol. 2021 Jul 6. doi: 10.3389/fonc.2021.682859 .